Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
159 hedge funds and large institutions have $706M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2022 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 39 increasing their positions, 47 reducing their positions, and 23 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
64% more call options, than puts
Call options by funds: $46M | Put options by funds: $28.1M
57% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 23
9% more funds holding
Funds holding: 146 → 159 (+13)
16% less capital invested
Capital invested by funds: $841M → $706M (-$135M)
17% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$50.2M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$29.2M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$20.1M |
| 4 |
FAM
Fred Alger Management
New York
|
+$17M |
| 5 |
Millennium Management
New York
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$67.6M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$53.7M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$27.7M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$21.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$13.4M |
RETA Hedge Fund Activity: Q3 2022 in Review
159 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q3 2022, worth a combined $706M — down 16% from $841M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new RETA positions and 23 closed out — a net gain of 13 holders — while 39 added to existing stakes and 47 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $50.2M. The largest seller was Wellington Management Group, cutting an estimated $67.6M.
- 159 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q3 2022, up from 146 in Q2 2022.
- Funds reported $706M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q3 2022, down 16% quarter-over-quarter.
- 36 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q3 2022 and 23 closed out, a net change of +13 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q3 2022 was Point72 Asset Management, an estimated $50.2M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q3 2022 was Wellington Management Group, an estimated $67.6M sold.
Based on aggregated 13F filings for Q3 2022.